


RECEIVED

OCT 11 2002

Attorney Docket No. 950376D1/HG



TECH CENTER 1600/2900

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Applicants : Tohru TAKAHASHI et al.

Serial No. : 09/842,347

Filed : April 25, 2001

For : EXPRESSION SYSTEM  
UTILIZING AUTOLYZING  
FUSION PROTEINS AND A  
NOVEL REDUCING POLYPEPTIDE

Art Unit : 1652

Examiner : Fronda

Express Mail Mailing Label

No.: EV 215 859 241 US

Date of Deposit: October 8, 2002

I hereby certify that this paper is #8/Pat 10-1602  
being deposited with the United  
States Postal Service "Express Mail  
Post Office to Addressee" service  
under 37 CFR 1.10 with sufficient  
postage on the date indicated above  
and is addressed to the  
Commissioner for Patents,  
Washington, D.C. 20231

Dorothy DeFrancesco  
Dorothy DeFrancesco

In the event that this Paper is late  
filed, and the necessary petition  
for extension of time is not filed  
concurrently herewith, please  
consider this as a Petition for the  
requisite extension of time, and to  
the extent not tendered by check  
attached hereto, authorization to  
charge the extension fee, or any  
other fee required in connection  
with this Paper to Account No.  
06-1378.

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
Washington, D.C. 20231

S I R :

This is a response to the Office Action of September 18,  
2002 (Paper No. 7) which is a Restriction Requirement under  
35 USC 121. The term for responding to the Office Action ends on  
October 18, 2002.

R E M A R K S

The Examiner is respectfully requested to acknowledge  
applicants' claim for priority under 35 USC 119 and receipt of  
the certified copies of the priority documents that were filed in  
the grandparent application Serial No. 08/500,635 on November 27,  
1995.

The Examiner is also respectfully requested to return a copy of the Form PTO-1449 filed on April 25, 2001 and to indicate thereon that the cited publications were considered and made of record.

Restriction was required under 35 USC 121 as follows:

Group I. Claims 48, 55, 60 and 80, drawn to a polypeptide;

Group II. Claims 61, 63, 89 and 90, drawn to methods of prophylaxis or treatment; and

Group III. Claims 71 to 75 and 77 to 79, drawn to antibodies to KM31-7.

Applicants elect Group I (claims 48, 55, 60 and 80).

It is noted that claim 77 is not drawn to an antibody, but rather to a process for the purification of KM31-7 protein.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,

Frishauf, Holtz, Goodman  
& Chick, P.C.  
767 Third Ave., 25th Floor  
New York, NY 10017-2023  
Tel. No. (212) 319-4900  
Fax No.: (212) 319-5101  
RSB/ddf

  
\_\_\_\_\_  
Richard S. Barth  
Reg. No. 28,180